CN101124222A - 用作毒蕈碱激动剂的四氢喹啉类似物 - Google Patents

用作毒蕈碱激动剂的四氢喹啉类似物 Download PDF

Info

Publication number
CN101124222A
CN101124222A CNA200580048487XA CN200580048487A CN101124222A CN 101124222 A CN101124222 A CN 101124222A CN A200580048487X A CNA200580048487X A CN A200580048487XA CN 200580048487 A CN200580048487 A CN 200580048487A CN 101124222 A CN101124222 A CN 101124222A
Authority
CN
China
Prior art keywords
optional
branched
straight
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580048487XA
Other languages
English (en)
Chinese (zh)
Inventor
尼尔斯·肖杰埃贝克
克瑞斯蒂恩·鲁普·科克
博·伦纳特·弗里贝里
博-拉格纳·托尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Priority to CN201210222989.1A priority Critical patent/CN102796095B/zh
Publication of CN101124222A publication Critical patent/CN101124222A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA200580048487XA 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物 Pending CN101124222A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210222989.1A CN102796095B (zh) 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/019,556 US7550459B2 (en) 2001-12-28 2004-12-21 Tetrahydroquinoline analogues as muscarinic agonists
US11/019,556 2004-12-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210222989.1A Division CN102796095B (zh) 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物

Publications (1)

Publication Number Publication Date
CN101124222A true CN101124222A (zh) 2008-02-13

Family

ID=36123554

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200580048487XA Pending CN101124222A (zh) 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物
CN201210222989.1A Expired - Fee Related CN102796095B (zh) 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210222989.1A Expired - Fee Related CN102796095B (zh) 2004-12-21 2005-12-15 用作毒蕈碱激动剂的四氢喹啉类似物

Country Status (16)

Country Link
US (3) US7550459B2 (cg-RX-API-DMAC10.html)
EP (1) EP1828176A1 (cg-RX-API-DMAC10.html)
JP (1) JP5114208B2 (cg-RX-API-DMAC10.html)
KR (2) KR101380794B1 (cg-RX-API-DMAC10.html)
CN (2) CN101124222A (cg-RX-API-DMAC10.html)
AR (1) AR052343A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005319426B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0517485A (cg-RX-API-DMAC10.html)
CA (1) CA2591766C (cg-RX-API-DMAC10.html)
IL (2) IL184065A (cg-RX-API-DMAC10.html)
MX (1) MX2007007588A (cg-RX-API-DMAC10.html)
NO (1) NO20073183L (cg-RX-API-DMAC10.html)
NZ (1) NZ555994A (cg-RX-API-DMAC10.html)
RU (1) RU2434865C2 (cg-RX-API-DMAC10.html)
TW (2) TWI433848B (cg-RX-API-DMAC10.html)
WO (1) WO2006068904A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242230A (zh) * 2013-05-02 2013-08-14 陕西步长高新制药有限公司 一种喹啉酮衍生物及其制备方法
CN115073370A (zh) * 2021-03-10 2022-09-20 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009106534A1 (en) * 2008-02-26 2009-09-03 H. Lundbeck A/S Novel heterocyclic carboxamides as m1 agonists
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
JP2016513677A (ja) * 2013-03-15 2016-05-16 アカディア ファーマシューティカルズ インコーポレイテッド ムスカリンアゴニスト
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365457A (en) 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3324137A (en) 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
US3364457A (en) * 1966-05-13 1968-01-16 Navy Usa Electrical adapter
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
CA2050264A1 (en) * 1990-08-30 1992-03-01 Raymond Baker Substituted pyrazine and its salts, compositions containing them and their use in medicine
US5093333A (en) * 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system
US5149815A (en) 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5378698A (en) 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5457099A (en) * 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
JPH0673011A (ja) * 1992-07-02 1994-03-15 Sawai Seiyaku Kk カルボスチリル誘導体および抗アレルギー剤
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JPH0881442A (ja) * 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
EP0934932A4 (en) 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
KR100672186B1 (ko) 1998-03-31 2007-01-19 아카디아 파마슈티칼스 인코포레이티드 무스카린 수용체에 대해 활성을 갖는 화합물
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
CZ20022603A3 (cs) 1999-12-30 2002-10-16 H. Lundbeck A/S 4-fenyl-1-piperazinylové deriváty
NZ521576A (en) 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
TWI310035B (en) 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
CN1777425A (zh) * 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242230A (zh) * 2013-05-02 2013-08-14 陕西步长高新制药有限公司 一种喹啉酮衍生物及其制备方法
CN103242230B (zh) * 2013-05-02 2015-02-18 陕西步长高新制药有限公司 一种喹啉酮衍生物及其制备方法
CN115073370A (zh) * 2021-03-10 2022-09-20 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途
CN115073370B (zh) * 2021-03-10 2024-12-17 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途

Also Published As

Publication number Publication date
WO2006068904A1 (en) 2006-06-29
US9522906B2 (en) 2016-12-20
AR052343A1 (es) 2007-03-14
AU2005319426B2 (en) 2011-10-13
EP1828176A1 (en) 2007-09-05
CN102796095B (zh) 2015-09-09
US20140221364A1 (en) 2014-08-07
US8680115B2 (en) 2014-03-25
JP2008524328A (ja) 2008-07-10
AU2005319426A1 (en) 2006-06-29
AU2005319426A2 (en) 2006-06-29
TWI433848B (zh) 2014-04-11
TW201414731A (zh) 2014-04-16
CN102796095A (zh) 2012-11-28
IL219920A (en) 2016-04-21
JP5114208B2 (ja) 2013-01-09
KR20070090003A (ko) 2007-09-04
IL184065A (en) 2015-09-24
RU2007127849A (ru) 2009-01-27
NO20073183L (no) 2007-09-17
CA2591766A1 (en) 2006-06-29
RU2434865C2 (ru) 2011-11-27
KR20130095846A (ko) 2013-08-28
US20090239903A1 (en) 2009-09-24
IL219920A0 (en) 2012-06-28
CA2591766C (en) 2014-09-09
US7550459B2 (en) 2009-06-23
KR101380794B1 (ko) 2014-04-04
US20050209226A1 (en) 2005-09-22
IL184065A0 (en) 2007-10-31
NZ555994A (en) 2010-09-30
TW200634006A (en) 2006-10-01
BRPI0517485A (pt) 2008-10-14
MX2007007588A (es) 2007-08-08

Similar Documents

Publication Publication Date Title
CN102796095B (zh) 用作毒蕈碱激动剂的四氢喹啉类似物
CN100402032C (zh) 用作毒蕈碱激动剂的四氢喹啉类似物
JP7083087B2 (ja) それに関連する障害の治療または予防に有用なβ－３アドレナリン受容体調節剤
EP2947085B1 (en) Oxazolidone compounds, method for preparing and application thereof
SA95150523B1 (ar) عوامل مضادة لمستقبل تاكيكينين tachykininمشتقة من مورفولين morpholineوثيومورفولين thiomorpholine
JP2021121612A (ja) 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
AU2008240728B2 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
KR20250006217A (ko) 통증 치료를 위한 Naν1.8의 바이사이클릭 헤테로사이클릭 아미드 억제제
JP3385318B2 (ja) キノリン−４−イル誘導体ｉｉ
JP5769504B2 (ja) 医薬
WO1999028307A1 (en) Alicyclic acylated heterocyclic derivatives
HK1074573B (en) Tetrahydroquinoline analogues as muscarinic agonists
CN101392001A (zh) 氨甲酰类衍生物、其制备方法及其在医药上的用途
WO1994027996A1 (en) 1,2,5-thiadiazole derivatives, their preparation and use
CN102796075B (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
EP2254866A1 (en) Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptatke inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080213